

Recent Modalities in the Management of Infective Endocarditis in Pediatric Patient

Essay

**Submitted for Fulfillment Of a master degree (MSC) in
Pediatrics**

By

Eitmad Mahmoud Khamess

Faculty of Medicine – Cairo University

Under supervision of

Prof . Dr . Faten M. Abd El Aziz

Professor of Pediatrics

Faculty of medicine – Cairo University

Prof .Dr . Rasha Ibrahim Ammar

Assistant professor of Pediatrics

Faculty of Medicine – Cairo University

Dr . Aya Mohammed Fattouh

Lecturer Of Pediatrics

Faculty of medicine – Cairo University

Faculty of Medicine

Cairo University

2007-2008



Acknowledgement

First, last and above all, thanks and gratitude to Allah for all his gift who enable me to complete this work.

I would like to express my great thanks and gratitude to professor Dr.Faten Abdel Aziz professor of pediatric Cairo university for all her help she offered me,her precious type and wise direction for me to complete this work.

I am also deeply grateful to professor Dr. Rash Ammar assistant professor of pediatric Cairo university and Dr.Aya Fatouaah lecturer of pediatric Cairo university for their continuous help and scientific support .

I want to thank professor Dr Amr Megahed professor of pediatric Zakazek university and professor Dr.Mortada El Shabrawy professor of pediatric Cairo university for their acceptance my discussion .

Finally,I am also grateful to my mother,my husband, my children and all my family for their continuous support and encouragement.



Abstract

Recent Modalities in the Management of Infective Endocarditis in Pediatric Patient

**Abdel Aziz, Faten M.; Ammar, Rasha I; Fattouh, Iya M and
Khamiss, Eitmad M.**

Infective endocarditis (IE) is an infection of the endocardium. It is not a common disease in pediatric but it because a high rate of morbidity and mortality. Modified Duke criteria are used for diagnosis of (IE) depending on major and minor criteria. Diagnosis of (IE) depends mainly on blood culture and echocardiography. Two major modalities are used in the treatment of (IE):- Antimicrobial therapy and surgical treatment.

Recently, in 2007, the American heart association had made recommendation for prevention of (IE) that so different from recommendation promoted over 50 years ago.

Key words:

Infective endocarditis (IE) – Duke criteria – Blood culture
Echocardiography.



Index

| Chapter | Content | Page |
|----------|--|------|
| 1 | Infective endocarditis | 1 |
| | Definition | 1 |
| | Classification | 1 |
| | pathogenesis of infective endocarditis | ۳ |
| | Microbiology | ۷ |
| | Pathology and complications | 1۰ |
| | Clinical presentation | 1۴ |
| 2 | Diagnosis of infective endocarditis | 2۲ |
| | Diagnostic criteria for infective endocarditis | 23 |
| | Duke criteria | 25 |
| | Blood cultures | 35 |
| | Approach to the Patient With blood culture–negative IE | 38 |
| | Role of echocardiography in the diagnosis of infective endocarditis | 4۶ |
| ۳ | Treatment of Infective Endocarditis | ۵۶ |
| | Antimicrobial chemotherapy | ۵۶ |
| | Treatment of highly penicillin-susceptible Viridans Group Streptococci and S bovis(MIC \leq 0.12 μ g/mL) | ۵۸ |
| | Treatment of Viridans Group Streptococci and S bovis With Penicillin MIC >0.12 to \leq 0.5 μ g/mL | ۵۹ |
| | Treatment of Viridans Group Streptococci With Penicillin MIC >0.5 μ g/mL | ۵۹ |



| | |
|---|-----|
| Treatment of prosthetic valves endocarditis caused by Viridans Group Streptococci and S bovis | ٦٠ |
| Treatment of native valve endocarditis caused by Staphylococci | ٦٤ |
| Treatment of endocarditis in the presence of prosthetic valves caused by Staphylococci | ٦٨ |
| Treatment of endocarditis caused by Enterococci | ٧١ |
| Treatment of endocarditis caused by HACEK microorganisms | ٧٦ |
| Treatment of endocarditis caused by Pseudomonas species | ٧٧ |
| Therapy for culture-negative endocarditis | ٧٧ |
| Fungal endocarditis | ٨٢ |
| Surgical approaches | ٨٤ |
| Antiplatelet and anticoagulant treatment | ٨٧ |
| The future in treatment of infective endocarditis | ٨٨ |
| ٤ prevention of infective endocarditis | ٨٩ |
| History of American Heart Association statements on prevention of infective endocarditis | ٨٩ |
| Cardiac conditions and endocarditis prophylaxis | ٩١ |
| Procedures that can cause bacteremia | ٩٤ |
| Recommended prophylactic regimens by(AHA) 1997 | ٩٩ |
| Recommended prophylactic regimens by(AHA) 2007 | ١٠٣ |



List of tables

| No. | Title | Page |
|-----|---|------|
| 1 | Microorganisms associated with spontaneous or procedure related transient bacteremia. | 5 |
| 2 | Complication of infective endocarditis. | 13 |
| 3 | Von Reyn Criteria for the diagnosis of infective endocarditis. | 24 |
| 4 | Duke Clinical Criteria for diagnosis of IE. | 26 |
| 5 | Definitions of terms used in the Duke Criteria for the diagnosis of IE. | 27 |
| 6 | Definition of infective endocarditis according to the modified Duke Criteria. | 31 |
| 7 | Definition of terms used in the Modified Duke Criteria for the diagnosis of infective endocarditis. | 32 |
| 8 | Proposed histological criteria for diagnosis of infective endocarditis. | 34 |
| 9 | HACEK group bacteria. | 41 |
| 10 | Common agents of blood culture-negative endocarditis. | 45 |
| 11 | The sensitivity and specificity of (TTE) and (TEE) in the diagnosis of vegetations. | 47 |
| 12 | Sensitivity of TEE versus TTE in the diagnosis of prosthetic valve endocarditis. | 48 |
| 13 | Therapy for endocarditis caused by Staphylococci in the absence of prosthetic materials. | 61 |
| 14 | Therapy for prosthetic valve endocarditis caused by Staphylococci. | 62 |
| 15 | Therapy of native valve endocarditis caused by highly Penicillin-susceptible viridans group streptococci and streptococcus bovis. | 63 |



| | | |
|----|---|----|
| 16 | Therapy of native valve endocarditis caused by strains of viridans group Streptococci and Streptococcus bovis relatively resistant to penicillin. | 69 |
| 17 | Therapy for endocarditis of prosthetic valves or other prosthetic material caused by viridans group Streptococci and Streptococcus bovis. | 70 |
| 18 | Therapy for native valve or prosthetic valve enterococcal endocarditis caused by strains susceptible to Penicillin, Gentamicin, and Vancomycin . | 72 |
| 19 | Therapy for native or prosthetic valve enterococcal endocarditis caused by strains susceptible to Penicillin, Streptomycin, and Vancomycin and resistant to Gentamicin. | 73 |
| 20 | Therapy for native or prosthetic valve enterococcal endocarditis caused by strains resistant to Penicillin and susceptible to Aminoglycoside and Vancomycin . | 74 |
| 21 | Therapy for native or prosthetic valve enterococcal endocarditis caused by strains resistant to Penicillin, Aminoglycoside, and Vancomycin. | 75 |
| 22 | Therapy for both native and prosthetic valve endocarditis caused by HACEK microorganisms. | 76 |
| 23 | Therapy for culture-negative endocarditis including Bartonella endocarditis. | 80 |
| 24 | Epidemiological clues in etiological diagnosis of culture-negative endocarditis. | 81 |
| 25 | Classification cardiac conditions on the basis of potential outcome if endocarditis occurs. | 96 |



| | | |
|----|--|-----|
| 26 | Dental procedures and endocarditis prophylaxis. | 97 |
| 27 | Respiratory, gastrointestinal and genitourinary tract procedures for which prophylaxis is or is not recommended. | 98 |
| 28 | Endocarditis prophylactic regimens for dental, oral, respiratory tract and esophageal procedures. | 100 |
| 29 | Endocarditis Prophylactic regimens for genitourinary and gastrointestinal procedures. | 102 |
| 30 | Cardiac conditions associated with the highest risk of adverse outcome from endocarditis for which Prophylaxis with dental procedures is reasonable by (AHA) 2007. | 107 |
| 31 | Dental Procedures for which endocarditis Prophylaxis is reasonable by (AHA) 2007. | 109 |
| 32 | Regimens for a dental Procedure reasonable by (AHA) 2007. | 110 |
| 33 | Prophylaxis for dental procedures recommended by(BSAC) 2006. | 114 |
| 34 | Antibiotic prophylaxis for dental procedures recommended by (BSAC) 2006. | 115 |
| 35 | Cardiac conditions for which antibiotic prophylaxis is indicated for non-dental procedures recommended by(BSAC) 2006. | 116 |
| 36 | Gastrointestinal procedures associated with endocarditis and prophylaxis recommendation by(BSAC) 2006. | 117 |
| 37 | Respiratory tract procedures associated with endocarditis and prophylaxis recommendation by(BSAC) 2006. | 118 |
| 38 | Genitourinary procedures associated with endocarditis and prophylaxis recommendation by (BSAC) 2006. | 118 |



| | | |
|----|---|-----|
| 39 | Recommended prophylactic antibiotic regimens for genitourinary, gastrointestinal or respiratory procedures in patients at risk of endocarditis recommended by(BSAC) 2006. | 119 |
|----|---|-----|

List of Figures

| No. | Title | Page |
|------------|--|-------------|
| 1 | Pathogenesis of infective endocarditis | 3 |
| 2 | Diagnostic approach to the use of Echocardiography in infective endocarditis | 53 |
| 3 | Suggested algorithm for determining the need for prophylaxis in patients with suspected mitral valve prolapse. | 93 |



List of abbreviation

| | |
|--------------|---|
| ABE | Acute bacterial endocarditis |
| AHA | American heart association |
| ASD | Atrial septal defect |
| BCNIE | Blood culture negative IE |
| BSAC | British Society for Antimicrobial Chemotherapy |
| CHD | Congenital heart disease |
| CHF | Congestive heart failure |
| CNS | Central nervous system |
| CoNS | Coagulase-negative staphylococci |
| ELIFA | Enzyme linked immunofluorescent assays |
| ELISA | Enzyme linked immunosorbent assays |
| ERCP | Endoscopic retrograde cholangiopancreatography |
| GI | Gastrointestinal |
| GU | Genitourinary tract |
| HACEK | Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae |
| HCM | Hypertrophic cardiomyopathy |
| IDUS | Intravenous drug users |
| IE | Infective endocarditis |
| INR | International normalized ratio |
| IVDA | Intravenous drug abusers |
| MIC | Minimum inhibitory concentration |
| MRSA | Methicillin resistant staphylococci |
| MVP | Mitral valve prolapse |



| | |
|-------------|---------------------------------------|
| NBTE | Nonbacterial thrombotic endocarditis |
| NIE | Nosocomial infective endocarditis |
| NVE | Native valve endocarditis |
| ORSA | Oxacillin-resistant <i>S aureus</i> |
| OSSA | Oxacillin-susceptible <i>S aureus</i> |
| PAS | Periodic acid-Schiff |
| PCR | Polymerase chain reaction |
| PDA | Patent ductus arteriosis |
| PVE | Prosthetic valve endocarditis |
| RHD | Rheumatic heart disease |
| SBE | Subacute bacterial endocarditis |
| TEE | Transoesophageal echocardiography |
| TTE | Transthoracic echocardiography |
| VSD | Ventricular septal defect |



Evaluation notes were added to the output document. To get rid of these notes, please order your copy of ePrint 5.0 now.

Introduction

Infective endocarditis (IE) is an infection of the endocardial surface of the heart. The intracardiac effects of this infection include severe valvular insufficiency, which may lead to intractable congestive heart failure and myocardial abscesses. IE not only affects the heart but also produces a wide variety of systemic signs and symptoms through several mechanisms, including both sterile and infected emboli and various immunological phenomena. (*Brusch, 2007*)

The incidence of infective endocarditis in the general population is 2-6 cases/ 100,000 patient. It is higher in patient with underlying valvular heart diseases and in intravenous drug abusers (IVDA).

(*Mylonakis and Calderwood,2001*)

Risk factors has been completely modified during the last 10 years. Rheumatic valve disease is no longer the main risk factor but others as: intracardiac device, IVDA , hemodialysis and nosocomial infection is also more frequent. (*Habib,2006*)

Despite advances in medical, surgical, and critical care interventions, infective endocarditis remains a disease that is associated with considerable morbidity and mortality. Early diagnosis and active treatment are critical for a better clinical outcome. However, infective endocarditis is difficult to diagnose because of the atypical clinical manifestations and frequent negative results from blood culture. Echocardiography plays an important role in the diagnosis and management of suspected or known infective endocarditis . (*Larry,2005*)



Chapter 1

Infective endocarditis

Infective endocarditis(IE) is an infection of the endocardium that usually involves the valves and adjacent structure . It can damage the valves and rings of connective tissues that surround the valves. As the valves of the heart do not actually receive any blood supply of their own, defense mechanisms (such as white blood cells) cannot enter. So if an organism (such as bacteria) establishes a hold on the valves, the body cannot get rid of them. Normally, blood flows smoothly through these valves. If they have been damaged , bacteria can have a chance to take hold. (*Morellion and Que, 2004*)

Classification

Traditionally, IE has been clinically divided into acute and subacute (because the patients tend to live longer in subacute as opposed to acute) endocarditis. This classifies both the rate of progression and severity of disease. The subacute bacterial endocarditis (SBE) is often due to streptococci of low virulence and mild to moderate illness which progresses slowly over weeks and months, while acute bacterial endocarditis (ABE) is a fulminant illness over days to weeks, and is more likely due to *Staphylococcus aureus* which has much greater virulence, or disease-producing capacity. This terminology is now discouraged. The terms short incubation (meaning less than about six weeks), and long incubation (greater than about six weeks) are preferred. (*Cunha et al.,1996*)




IE may also be classified as culture-positive or culture-negative. Culture-negative endocarditis is due to prior antibiotic administration or microorganisms that require a longer period of time to be identified in the laboratory. Such organisms are said to be 'fastidious' because they have demanding growth requirements. Some pathogens responsible for culture-negative endocarditis include *Aspergillus* species, *Brucella* species, *Coxiella burnetii*, *Chlamydia* species, and HACEK bacteria (ie, *Haemophilus aphrophilus*, *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, *Kingella kingae*) (**Houpikian and Raoult ,2005**)

The distinction between native-valve endocarditis and prosthetic-valve endocarditis is clinically important. Native valve endocarditis (NVE) is a microbial infection involving one or more of the natural heart valves. Streptococci, especially *viridans streptococci*, are responsible for the largest percentage of cases of (NVE). Prosthetic valve endocarditis (PVE) is an endovascular microbial infection occurring on parts of a valve prosthesis or on reconstructed native heart valves. (PVE) develops in 2 to 3% of patients within 1 yr after valve replacement and in 0.5%/yr thereafter. It is more common after aortic than after mitral valve replacement. Early-onset infections (< 2 mo after surgery) are caused mainly by contamination during surgery with antimicrobial-resistant bacteria (eg, *S. epidermidis* is the usual cause of early-onset PVE nearly 30% of cases, diphtheroids, coliform bacilli, *Candida* sp, *Aspergillus* sp). Late-onset infections are caused mainly by contamination with low-virulence organisms during surgery or by transient asymptomatic bacteremias, most often with streptococci, *S. epidermidis*, diphtheroids, the fastidious gram-negative bacilli and *Haemophilus* species . (**Piper et al.,2001**)



Patients who are injected intravenously may introduce infection which will travel to the right side of the heart. In other patients without a history of intravenous exposure, endocarditis is more frequently left-sided. (Jennifer,2000)

Figure 1:pathogenesis of infective endocarditis



(Morellion and Que, 2004)

Intact cardiac endothelium is a poor stimulator of blood coagulation and is weakly receptive to bacterial attachment. Damaged or denuded endothelium is a potent inducer of thrombogenesis and provides a nidus to which bacteria can adhere and eventually form an infected vegetation. In children with heart disease, the shear force associated with an abnormal high-velocity jet stream of blood can damage the endothelium. Thrombogenesis at such a site results in the deposition of sterile clumps of platelets, fibrin, and occasionally red blood cells, and the formation of nonbacterial thrombotic endocarditis (NBTE). NBTE also can be produced in children with indwelling intravenous catheters positioned in the right side of the heart. Such catheters may traumatize the endocardium or valvular endothelium, exposing the subendothelial collagen. (Baltimore,1990)

